Patients with limited-stage small cell lung cancer (LS-SCLC) receiving once-daily thoracic radiation reported better quality of life (QoL) at 3 weeks but worse outcomes at 12 weeks compared to twice-daily regimens, according to the CALGB-70702 trial, though clinicians noted practical advantages to the once-daily approach.
The CALGB-70702 trial, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8504), compared once-daily and twice-daily radiation for LS-SCLC, revealing nuanced QoL trade-offs. Patients in the once-daily arm—receiving 70-Gy once-daily thoracic radiotherapy—experienced less inconvenience and better short-term QoL, but their scores declined significantly by 12 weeks, while the twice-daily group (standard 45-Gy twice-daily regimen) saw initial declines that stabilized later.
QoL Fluctuations Highlight Treatment Trade-Offs
At 3 weeks, the once-daily regimen showed significantly better FACT-L TOI scores (P=.003) and less acute esophagitis compared to twice-daily treatment. However, by 12 weeks, the once-daily group’s QoL worsened, with higher difficulty swallowing and esophagitis scores. The once-a-day arm was considered to be less inconvenient by most patients and will probably end up being what is done in practice going forward, said Apar Kishor Ganti, MD.
Patients with SCLC Report Better Quality of Life with
Kristin Ann Higgins, MD, a discussant from Emory University’s Winship Cancer Institute in Atlanta, noted that the 12-week dip in once-daily QoL mirrored the timing of the twice-daily regimen’s final week, suggesting temporal factors influenced outcomes. Quality of life differs for the different fractionation regimens, and it differs depending on where in time you analyze quality of life, she said. The study enrolled 417 patients, with 87% completing baseline questionnaires and 71% at week 52.
Clinical Reactions: Convenience vs. Long-Term Risks
While the once-daily approach was praised for practicality, clinicians cautioned about long-term implications. Joe Y. Chang, MD, PhD, of MD Anderson Cancer Center called the acute toxicities not having enough significance for clinicians to choose which regimen [to use], emphasizing that other factors, including long-term toxicity, could play more of a role in this setting. Other factors, including long-term toxicity, could play more of a role in this setting, he said.
However, the study’s primary endpoints were FACT Trial Outcome Index-Lung Cancer (FACT-L TOI) and FACT eating and swallowing subscales at 12 weeks—favored the twice-daily regimen, though the difference was marginal. The clinical benefit of both regimens is similar, but the once-daily schedule’s convenience may sway real-world adoption, Ganti noted.
Unanswered Questions: Long-Term Outcomes and Patient Preferences
Therapeutic controversies over use of antioxidant supplements during cancer
The trial’s focus on QoL rather than survival left lingering questions. While both regimens showed comparable overall survival in the broader CALGB 30610 study, the QoL data suggests patient preferences could shape treatment decisions. If you consider once-daily radiation that would occur at week 7… we do see a similar dip of quality of life at week 7 for the once-daily radiation arm, Higgins said, highlighting the need for longitudinal studies.
Experts agreed that the choice between regimens hinges on balancing short-term comfort with long-term risks. The acute toxicities don’t have enough significance for clinicians to choose which regimen [to use], Chang reiterated, urging further research into long-term side effects. The study also revealed that one-quarter of patients in the once-daily arm felt treatment was inconvenient, compared to one-third in the twice-daily arm.
What Comes Next: Implications for LS-SCLC Treatment
The CALGB-70702 findings underscore the complexity of LS-SCLC care, where QoL and practicality often outweigh minor survival differences. Clinicians are now weighing patient-reported outcomes against long-term toxicities, with the once-daily regimen gaining traction for its convenience. However, the trial’s limitations—such as its substudy status and focus on short-term QoL—mean further research is needed to guide long-term decisions.
Pregabalin for chronic cough due to lung cancer
As treatment protocols evolve, the balance between clinical efficacy, patient experience, and logistical feasibility will remain central. For now, the study provides a critical framework for understanding how radiation schedules impact real-world patient outcomes, even as it leaves room for future exploration of long-term consequences.
The CALGB-70702 trial is a planned substudy of the CALGB 30610 study that demonstrated that 70-Gray (Gy) once-daily thoracic radiotherapy did not have superior overall survival compared with the standard 45-Gy twice-daily regimen in LS-SCLC. Since both arms provided similar clinical benefit, the researchers examined other factors like QoL to help guide decision-making. Patients were administered several QoL questionnaires at baseline and a single item assessing difficulty swallowing at baseline and 3, 5, 7, 12, 26, and 52 weeks after radiation initiation. The primary endpoints were FACT Trial Outcome Index-Lung Cancer (FACT-L TOI) and FACT eating and swallowing subscales at 12 weeks.
Consent was obtained from 417 patients, with a questionnaire completion rate of 87% at baseline and 71% at week 52. The once-daily arm showed significantly lower FACT-L total score mean worsening compared with the twice-daily arm at week 3, but this was only marginally less at week 5. The FACT-L TOI mean worsening was significantly less at 3 weeks (P=.003) for the once-daily arm, but was significantly greater at 12 weeks compared with the twice-daily arm. Mean increases in acute esophagitis score and difficulty swallowing were significantly greater in the twice-daily arm at week 3 as well. However, at week 12, acute esophagitis score and difficulty swallowing was worse in the once-daily arm.
One-quarter of patients in the once-daily arm felt treatment was inconvenient compared with one-third in the twice-daily arm. The study discussant, Kristin Ann Higgins, MD, highlighted the temporal relationship between the timing of the twice-daily regimen’s final week and the QoL decline in the once-daily group, emphasizing the importance of longitudinal analysis. The trial’s findings reflect a critical shift in treatment prioritization, where patient-reported outcomes and logistical considerations may outweigh minor differences in survival metrics.
Apar Kishor Ganti, MD, presenting the results, noted that while the once-daily regimen’s QoL advantages at 3 weeks were statistically significant, the long-term decline at 12 weeks necessitates further investigation. The study’s design, as a substudy of CALGB 30610, underscores the evolving role of QoL assessments in shaping clinical practice, even as it highlights the need for continued research into the long-term implications of radiation scheduling.
